|1.||Zeuzem, Stefan: 21 articles (10/2015 - 10/2002)|
|2.||Ferenci, Peter: 19 articles (01/2014 - 05/2004)|
|3.||Marcellin, Patrick: 15 articles (01/2015 - 02/2004)|
|4.||Shiffman, Mitchell L: 14 articles (04/2014 - 09/2002)|
|5.||Rodriguez-Torres, Maribel: 11 articles (05/2013 - 07/2004)|
|6.||Fried, Michael W: 11 articles (10/2008 - 09/2002)|
|7.||Rabasseda, X: 11 articles (09/2007 - 01/2003)|
|8.||Prous, J R: 11 articles (09/2007 - 01/2003)|
|9.||Reddy, K Rajender: 10 articles (01/2015 - 09/2002)|
|10.||Lawitz, Eric: 8 articles (02/2015 - 08/2008)|
|1.||Chronic Hepatitis C
01/01/2011 - "Trial 2 randomized 60 adult patients with chronic hepatitis C to 180 μg peginterferon alfa-2a once weekly by the autoinjector or prefilled syringe for 3 weeks followed by the alternative device (prefilled syringe or autoinjector, respectively) for 3 weeks. "
05/01/2006 - "We compared characteristics of chronic hepatitis C patients with patients with normal and elevated ALT levels using data from 3 randomized phase III trials of peginterferon alfa-2a (40 kDa). "
01/01/2015 - "There was no significant difference in the SVR rates and safety profile between chronic hepatitis C patients treated with the PEG-IFN alfa-2a and alfa-2b."
04/01/2014 - "A total of 3070 treatment-naive, chronic hepatitis C genotype 1-infected patients were treated for up to 48 weeks with peg-IFN alfa-2b 1.5 µg/kg/week or 1 µg/kg/week, or peg-IFN alfa-2a 180 µg/week plus RBV. "
11/01/2013 - "Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype."
07/01/2004 - "In October 2002, the US Food and Drug Administration approved peginterferon alfa-2a for the management of chronic hepatitis C virus (HCV) infection. "
02/01/2007 - "We conducted a prospective study to investigate the tolerability and efficacy of PEG-IFN alpha-2a (135 microg weekly for 48 weeks) in six dialysis patients with chronic HCV infection. "
11/01/2014 - "The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection."
04/01/2011 - "In multivariate logistic regression analysis, positive predictors of SVR were HCV genotype 2 infection, HCV genotype 3 infection, low baseline viral load and treatment with peginterferon alfa-2a. "
06/01/2010 - "Untreated HIV-1-infected volunteers without HCV infection received 180 microg of pegylated interferon alfa-2a weekly for 12 weeks. "
|3.||Chronic Hepatitis B
12/01/2009 - "To compare the efficacy of 48 weeks vs 24 weeks of therapy with peginterferon alfa-2a, in patients with chronic hepatitis B who had good predictors of response. "
01/01/2012 - "A total of 113 chronic hepatitis B patients under peginterferon alfa-2a (40KD; 180 μg/week) treatment were included in this multicenter, open label, non-interventional study, and 66 patients completed the follow-up period. "
03/01/2008 - "The 2 reported trials investigated the effectiveness of treatment with peginterferon alfa-2a in Asian patients with chronic hepatitis B (CHB). "
01/01/2007 - "The aim of the study was to assess the viral response after 4 weeks of treatment with pegylated interferon alfa-2a chronic hepatitis B. "
01/01/2015 - "There is no information on the long-term effects of peginterferon (PEG-IFN) alfa-2a therapy for chronic hepatitis B (CHB) in Japan. "
01/01/2008 - "The aim of this study was to estimate the proportion of spontaneous viral clearance (SVC) after symptomatic acute hepatitis C and to evaluate the efficacy of 12 weeks of pegylated interferon alfa-2a in patients who did not clear the virus spontaneously. "
10/01/2015 - "Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders."
10/01/2009 - "Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial."
01/01/2008 - "Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a."
03/01/2007 - "We report a case of PEG-IFN alpha-2a induced pulmonary toxicity in a 50-year-old male patient with hepatitis C. "
08/01/2005 - "Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B."
11/01/2011 - "Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C."
04/01/2013 - "We evaluated an association with entecavir and pegylated interferon alfa-2a (PEG-IFN) in 20 patients with hepatitis B, high HBV viremia and genotypes A, B, C and E. "
06/01/2012 - "The aim of this analysis was to assess the renal function during combination therapy with peginterferon alfa-2a (PegIFNα-2a) plus ADV vs either drug alone in patients with hepatitis B/D co-infection. "
11/01/2009 - "Hepatitis B e antigen as a predictor for hepatitis B e antigen-positive chronic hepatitis B patients with peginterferon alfa-2a therapy."
|2.||Hepatitis B e Antigens
|4.||peginterferon alfa-2b (Pegintron)
|6.||Hepatitis B Surface Antigens (HBsAg)
|8.||Interferon Alfa-2a (Interferon Alfa 2a)
|9.||DNA (Deoxyribonucleic Acid)
|10.||Interferon Alfa-2b (Interferon Alfa 2b)
|3.||Renal Dialysis (Hemodialysis)